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Abstract 
Objective: To identify reference values for normal sensory and motor nerve conduction in upper and 
lower limb peripheral nerves in a study population in India. The work was carried out in advance 
of the INFIR Cohort Study, a prospective study of individuals with newly diagnosed multibacillary 
MB leprosy, the objective being to identify early changes in nerve function predictive of new onset 
impairment and reactions. Methods: We assessed sensory nerve conduction in bilateral ulnar, median, 
radial cutaneous and sural nerves and motor nerve conduction in distal and proximal sites in bilateral 
ulnar, median and peroneal nerves among 315 healthy subjects. After adjustment for skin temperature 
and removal of outliers reference values were computed using regression analysis of log-transformed 
data. The analysis and resulting reference values were stratifi ed by age and sex and based on the 
appropriate 5th or 95th percentiles. Results: Presented here are reference values for sensory nerve 
conduction velocity (SNCV), sensory nerve action potential (SNAP) amplitude and latency.  Also for 
motor nerve conduction velocity (MNCV) and compound motor action potential (CMAP) amplitude 
at proximal sites and for amplitude and latency at distal sites. In each case percentiles are given by 
sex within four 10 year age bands. For males aged 55 years old, the reference value for ulnar SNCV 
was 43.6 m/sec and SNAP amplitude was 7.43 μV. Ulnar MNCV at the proximal site in the elbow 
was 50.8 m/sec and CMAP amplitude 7.25 mV and at distal sites in the wrist the amplitude was 7.14 
mV and latency 3.1 msec. In the leprosy-affected cohort, the most common and therefore potentially 
the earliest impairment, is found in sensory nerve conduction amplitude of the sural nerve. 
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INTRODUCTION
Assessment of motor and sensory nerve conduction 
is a proven diagnostic tool in the testing of 
peripheral nerve damage.1 Electrophysiological 
assessment of sensory nerve action potential 
(SNAP), compound motor action potential 
(CMAP) amplitudes, sensory nerve conduction 
velocity (SNCV) and motor nerve conduction 
velocity (MNCV) help to characterise and 
quantify the sensory and motor functions in the 
large myelinated fi bres of peripheral nerves. 
Reference values are used to defi ne the limits 
of normal function, with test values outside the 
range suggesting the presence of some form of 
neuropathy. Small fi bre function is separately 
assessed with tests of pain, thermal perception, 
sweat or vasomotor function. Previous studies 
have reported differences in function related to 
ethnicity and demographic factors.2-4   
 The present paper is part of a series reporting 
normal reference values for a study population 
in northern India in advance of a prospective 
cohort study or individuals newly diagnosed 
with multibacillary leprosy. This is the fi rst 
large study to make prospective assessments of 
vibration perception, warm and cold sensation 
and nerve conduction in order to identify the 
earliest available indicator of changes in nerve 
function related to leprosy reactions. Since loss 
of sensation in leprosy brings an increased risk 
of secondary impairments, identifying the early 
indicators of nerve involvement is a primary 
concern. While the TRIPOD study5 suggested 
that prophylactic treatment of early involvement 
of large myelinated touch fi bers detected by 
Neurology Asia April 2010
40
monofi lament was not appropriate, alternative 
forms of nerve function assessment may detect 
other forms of nerve involvement, including those 
functions fi rst affected.
 The research was centred on the specialist 
leprosy referral centres in Naini and Faizabad, 
Uttar Pradesh, northern India, run by The Leprosy 
Mission International. Early fi ndings of the Cohort 
Study have already been published.6-10     
METHODS 
Subject selection and sample size
Determination of the limits of normal function 
requires the collection and analysis of data from 
healthy subjects without a neurological condition 
drawn from a defi ned population group. In order to 
achieve a close match with individuals recruited to 
the cohort study we recruited subjects from among 
the healthy relatives accompanying individuals 
attending general and dermatology outpatient 
clinics at the two participating centres, applying 
inclusion and exclusion criteria as follows:
Inclusion criteria: Individuals were selected to 
obtain an equal number of male and female study 
subjects and by age group. In order to ensure the 
closest possible match with individuals recruited 
to the subsequent Cohort Study, equal numbers of 
subjects were included within four age bands up 
to 60 years, the maximum age for recruitment. 
Exclusion criteria: Since the diagnosis of leprosy 
can only be made on clinical grounds all subjects 
were screened by an experienced leprologist 
leading to the exclusion of anyone exhibiting any 
clinical signs and symptoms of leprosy.  Subjects 
with any known neurological disorder, previous 
contact with leprosy or a history of diabetes 
were also excluded.  Individuals aged above 60 
years or those less than 10 years were excluded. 
Nerve conduction testing was concurrent with the 
parallel studies focussing on thermal sensation 
and vibration perception.  Some subjects were 
involved in more than one study.  
 To ensure adequate precision we studied 40 
subjects within each of the four age groups for 
men and for women. The overall target for the 
number of normal subjects was therefore 320, 
equal numbers to be recruited in each centre.
Equipment and procedures
The equipment used was a Neurocare 2000 
nerve conduction system supplied by BioTech 
(India). Data was saved in a standard Microsoft 
Access database. All testing was conducted 
in air-conditioned rooms with the temperature 
maintained in the range between 20 and 26˚C. 
Skin temperatures were recorded using a Testo 
Quicktemp electronic surface thermometer. 
Protocol for testing and data recording
The nerves and test sites matched those used in 
the Cohort Study. Testing was done bilaterally on 
the cutaneous area of fi ve nerves that are affected 
during leprosy neuropathy.  For antidromic 
sensory conduction in the upper limbs, the 
ulnar and median nerves supplying digits 5 and 
2 respectively, and the radial cutaneous nerve 
at the wrist, were studied. For the lower limb 
the sural nerve was studied behind the lateral 
malleolus. Action potentials were recorded at a 
standard distance of 14 cm in all nerves. Sensory 
testing produced assessments of SNCV and SNAP 
amplitude and latency for each nerve. Motor 
testing produced assessments of MNCV and 
CMAP amplitude and latency at proximal sites 
and CMAP amplitude and latency at distal sites 
for bilateral ulnar, median and peroneal nerves. All 
the neurophysiological tests were according to a 
standardised set-up with distances specifi ed. Skin 
temperatures were measured electronically at wrist 
and ankle bilaterally. Further details of the study 
design are available in earlier publications.11 
 Nerve conduction testing was undertaken 
by the team of physiotherapists, who were also 
responsible for vibration perception and thermal 
threshold testing. After initial extensive on-site 
training given by a qualifi ed neurophysiologist, 
four physiotherapists and a physio-technician 
in Naini and four physiotherapists in Faizabad 
completed inter-rater reliability testing. Within 
the centres each pairing was asked to complete 
up to 20 assessments of volunteer subjects. For 
this purpose we recruited subjects with a variety 
of neurological conditions that would ensure the 
assessors demonstrated reliability across the full 
range of nerve function. The results were analysed 
and demonstrated a good level of reliability.
Identifi cation of outliers and calculation of 
reference values
A total of 315 subjects were assessed. Since the 
data collection procedure was fully automated data 
checking focussed on the accuracy of demographic 
data and the availability of data from all subjects 
assessed. Prior to analysis all assessments of 
latency and velocity were normalised for a 
41
temperature of 33ºC using the standard formulae 
described by De Lisa et al.12
 In view of age-related changes in parameters 
of nerve conduction we adopted a regression-
based approach to identify outliers. For each 
assessment of latency, velocity and amplitude we 
used regression analysis of log-transformed data 
to compute age-adjusted estimates and identifi ed 
observations with standardised residual in excess 
of 2.58 as outliers. These were then excluded from 
the remaining analysis. In view of differences 
between centres as well as between sexes the 
procedure was carried out separately within 
four groups defi ned by centre and sex. The fi rst 
round of analyses proved effective in identifying 
the most extreme outliers. A judgement was 
then made as to whether the process should be 
repeated to remove further suspect assessments. 
The numbers of assessments excluded in this 
way are reported under the Results heading. In 
comparison to the procedure used in the earlier 
analyses, this procedure is more sensitive to 
differences between age and sex groups and results 
in a more conservative elimination of outliers. 
 Before computing reference values we used 
analysis of variance to assess differences between 
sexes, between age groups, between left and 
right sides and between centres. Left and right 
side assessments were then pooled, effectively 
doubling the sample size. We then used regression 
analysis of log transformed data on age within 
each sex and centre combination to compute the 
specifi c percentiles of normal limits.13 Finally 
these were reverse-transformed to the original 
units of amplitude, latency or velocity as 
appropriate. Presented here are reference values 
based on estimates of the 95th percentiles for 
sensory and for motor nerve conduction latency 
and 5th percentiles for amplitude and velocity. 
These are based on a re-analysis of the data used 
in an earlier publication6, the methods described 
here showing greater sensitivity to differences 
relating to sex and age.  
Application of reference values
The reference values presented here were applied 
to identify impairment rates (percentages) among 
the 303 newly diagnosed cases of multibacillary 
leprosy recruited to the prospective INFIR 
Cohort Study. Other papers in the present 
series14,15 describe reference values for vibration 
perception thresholds and for normal warm and 
cold sensation.  The fi rst of these provides more 
information on the cohort study.
Ethical Approval
Permission for all aspects of the INFIR study 
was obtained from the Indian Council of Medical 
Research through its Research Ethics Committee 
at the Central JALMA Institute for Leprosy in 
Agra gave ethical approval.  Written consent was 
obtained from subjects enrolled in the Cohort 
Study. From individuals participating as subjects 
in the present study we obtained informed verbal 
consent, the great majority of those approached 
being willing to participate. 
RESULTS
A total of 315 subjects were enrolled during the 
period from January 2000 up to July 2001. The 
distribution by age and sex is shown in Table 1. 
Mean age for men and women in Faizabad were 
41.0 years (standard deviation 13.2) and 39.4 
years (13.3) respectively and in Naini 39.7 years 
(13.5) and 37.9 years (13.6).   
 As a result of the two rounds of outlier 
elimination 0.95% of sensory assessments and 
0.77% of motor assessments were excluded.  
 The four sections of Table 2 present summary 
statistics for left and right side assessments by 
centre, sex and age group for sensory nerve 
conduction velocity and amplitude, for proximal 
motor nerve conduction velocity and amplitude 
and for distal motor nerve conduction latency and 
amplitude. To assess the statistical signifi cance 
of differences in assessments in each nerve 
relating to sex, age group and side we used 
analysis of variance of log-transformed data with 
age as a covariate. In the analyses of sensory 
assessments, there was a statistically signifi cant 
age effect in latency, amplitude and velocity for 
sural and radial cutaneous nerves (all p<0.01 or 
higher levels of signifi cance). Age also showed 
a statistically signifi cant association with median 
and ulnar SNAP amplitude (p<0.001 in each 
case), but not with latency or velocity in these 
nerves. Statistically signifi cant sex effects were 
found in all analyses relating to latency and 
velocity (p<0.05 or higher levels of signifi cance) 
but in none of those relating to amplitude. The 
importance of these differences is refl ected in the 
charts of Figure 1. No differences relating to side 
reached statistical signifi cance. Including centre 
in the analysis did not change these fi ndings, 
however, between centre differences reached 
statistical signifi cance in all latency and velocity 
assessments and in amplitude assessments only 
for the sural nerve.
 With the exception of ulnar CMAP distal 
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Faizabad
Age groups (years)
 Sex 30 yrs 31-40 yrs 41-50 yrs 51-60 yrs Total
 
 Female  21 20 21 18 80
  26.3, 52.5 25.0, 50.0 26.3, 52.5 22.5, 47.4 50.6
 Male 19 20 19 20 78
  24.4, 47.5 25.6, 50.0 24.4, 47.5 25.6, 52.6 49.4
 Total 40 40 40 38 158
  25.3 25.3 25.3 24.1 
Naini
Age groups (years)
 Sex 30 yrs 31-40 yrs 41-50 yrs 51-60 yrs Total
 
 Female  24 20 17 17 78
  30.8, 54.6 25.6, 51.3 21.8, 47.2 21.8, 44.7 49.7
 Male 20 21 22 20 84
  25.3, 45.5 24.1, 48.7 24.1, 52.8 26.6, 55.3 50.3
 Total 44 39 36 38 157
  28.0 24.8 22.9 24.3 
Table 1: Age and sex distribution plus row and column percentages for subjects assessed in two 
centres
latency, proximal and distal assessments in all three 
motor nerves showed a statistically signifi cant 
age-related trend (p<0.05 or less). For the ulnar 
nerve, there were statistically signifi cant age and 
sex interactions for MNCV and CMAP latency. 
There was also a statistically signifi cant sex effect 
for median and peroneal CMAP proximal latency 
(p<0.01 and p<0.05 respectively). There were 
no statistically signifi cant differences between 
left and right sides. Including a comparison 
between centres did not change these fi ndings. 
In all analyses differences between centres were 
statistically signifi cant (p<0.01 or less), the only 
exception being in CMAP proximal latency and 
CMAP distal amplitude for the median nerve. 
 For the remaining analysis we proceeded with 
calculation of thresholds based on pooled left and 
right side assessments.  The resulting thresholds 
based on the 95th percentile are presented in Table 
3, broken down by sex and four ten year age 
bands by centre and for combined centres. 
The association with age, sex and centre is evident 
in the trends in reference values presented in 
Table 3. This is reinforced in Figure 1, which 
presents scatter plots for sensory and motor 
nerve conduction assessments for the ulnar nerve 
overwritten with the 95th percentiles based on 
data from combined centres plus a shaded area 
illustrating the distance between centre-specifi c 
thresholds.
 Applying the thresholds based on centre, sex 
and age-specifi c 95th percentiles to assessments 
of the leprosy-affected cohort at time of diagnosis 
we computed impairment rates in all nerves (Table 
4).  These draw attention to the high rates of 
impairment found in the cohort and go far beyond 
the impaired rates identifi ed by monofi lament 
testing.7
 The scatter plots for the ulnar nerve presented 
in Figure 2 further illustrate the extent of impaired 
function found in the leprosy cohort.  In these 
charts a default extreme value was substituted 
for nerves found to be non-conducting.
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Figure 1.   Scatter plots of ulnar sensory nerve conduction amplitude and proximal and distal motor nerve conduction 
amplitude for normal subjects by age and by sex with 5th percentile based on combined centres plus 
shaded area highlighting the difference between centre-specifi c 5th percentiles. 
Chart 1B
Chart 1C Chart 1D
Chart 1A
Chart 1E Chart 1F
 Scatter plots and a full set of summary statistics, 
including additional 97.5th and 99th percentile, for 
all nerves and functions are available from the 
authors.
DISCUSSION
Conclusions based on NCS testing for neuropathy 
require comparison of individual results with 
established reference values.  In this study we 
collected data from subjects representative of the 
51
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Figure 2.   Scatter plots of ulnar SNAP amplitude and ulnar CMAP distal and motor amplitude for cohort cases 
by sex and by age with 5th percentile based on combined centres plus shaded area highlighting the 
difference between centre-specific 5th percentiles. 
Chart 2BChart 2A
Chart 2C Chart 2D
Chart 2E Chart 2F
53
local population. To best defi ne the limits of normal 
nerve function, reference values were calculated 
to include adjustment for known covariates and 
centre-related differences.  In the absence of left 
and right side differences, merging data from right 
and left side assessments gave greater precision 
in the estimation of the reference values at each 
test site.  These may now be used to assess nerve 
function in individuals for whom peripheral nerve 
function is at risk.   The mean values of SNAP 
amplitude and SNCV and proximal and distal 
CMAP latency and amplitude and MNCV in 
the present study correspond well with previous 
studies.16,17 The sources and implications of 
differences between centres have been discussed 
in the earlier papers in this series.14,,15
 Reference values based on percentiles were 
derived by regression-based methods, and are 
not therefore directly comparable with earlier 
published work defi ning abnormality as two or 
greater standard deviations from the mean. Like 
many diagnostic tools with moderate sensitivity 
and specifi city, it is advised that values “close” to 
the published reference value are not necessarily 
an indication of abnormality.18 However, a 
progression towards and beyond the reference 
value represents a new stage in nerve involvement 
that is likely to be of clinical importance.  
 Skin temperatures recorded in Faizabad ranged 
from 28.0˚C to 36.9˚C for hands and from 23.0˚C 
to 36.4˚C for the foot. The equivalent in Naini 
were 24.0˚C to 36.1˚C and 18.0˚C to 35.0˚C. In 
addition to the standard temperature correction 
we carried out a series of analyses exploring any 
remaining relationship between skin temperature 
and amplitude and velocity.  In all nerves and test 
sites for both sensory and motor nerve conduction 
we found skin temperature to be predictive of 
amplitude (p<0.001 in each case). We also looked 
for any continuing association between skin 
temperature and temperature-adjusted measures of 
SNCV, MNCV, and SNAP and CMAP amplitudes 
and latencies. While signifi cance levels were 
generally lower, we found statistically signifi cant 
temperature-related variation in all measures. The 
suggestion from these fi ndings is that the chosen 
approach to temperature adjustment was only 
partially successful in removing the temperature 
effect. In a smaller study this effect may not have 
been detectable. Further analysis of the present 
data may identify a more sensitive method of 
adjustment.
 The reference values reported here were used to 
assess the nerve status of newly diagnosed cases 
of multibacillary leprosy recruited to the Cohort 
study.  In relation to sensory nerve conduction 
our fi ndings match those of Arruda et al19 who 
found high rates of abnormality in sural nerve 
sensory action potential while conduction velocity 
was only mildly involved.  Our fi ndings also 
reinforce those of Husain and Malaviya20 who 
compared patients with and without manifest 
nerve damage and found reduced nerve conduction 
velocities and changes in latency and amplitude. 
Changes in sensory nerve conduction were most 
pronounced.  We found high impairment rates 
in lower limbs and also in the radial cutaneous 
nerve. Soysal et al21, working in Turkey, used 
nerve conduction to assess a series of newly-
diagnosed leprosy patients. They found that 
sensory impairment predominated over motor and 
identifi ed predominantly axonal polyneuropathy 
that was more severe in the lower extremities. 
Sensory nerve damage was accompanied by 
autonomic involvement. Together with the level of 
impaired function observed in the leprosy cohort, 
these fi ndings raise issues concerning treatment of 
these early indicators of nerve involvement and 
the choice of an appropriate treatment regime.  
 In conclusion, this is the fi rst large-scale study 
to publish reference values for a full set of nerve 
conduction parameters for a normal population 
in northern India. The reference values represent 
the limit to normal assessments for sensory and 
motor nerve conduction velocity and amplitude 
by sex and within 4 ten year age bands. While 
the research was conducted in preparation for a 
prospective study of people affected by leprosy, 
the data have potential applications in the 
assessment of nerve function in a wide range of 
neurological conditions.
 Applying these reference values to the data 
from the leprosy cohort draws attention to the 
high rates of impaired function among people 
affected by leprosy. Further analysis of the Cohort 
data will determine whether the presence of 
such impairment at diagnosis is a risk factor for 
the development of new impairment detectable 
by monofilament or muscle testing during 
and subsequent to treatment with multi-drug 
therapy. Questions also arise about the need for 
early treatment and the choice of an appropriate 
treatment regime. 
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